An anti–IL-5 for the add-on maintenance treatment of adults with severe asthma and an eosinophilic phenotype.1

Limitations of Use: CINQAIR is not indicated for:

  • treatment of other eosinophilic conditions
  • relief of acute bronchospasm or status asthmaticus

CINQAIR is a humanized monoclonal anti–IL-5 antibody that inhibits IL-5 from binding eosinophils.1

The mechanism of CINQAIR action in asthma has not been definitively established.1

Learn more about how CINQAIR works:

View the mechanism of action

Learn about the pharmacologic profile of CINQAIR:

Review data for the reduction of blood eosinophils

CINQAIR may be an appropriate treatment for patients who are 18 years of age and older with:

  • Severe asthma that is inadequately controlled despite standard of care (medium-high dose ICSs with LABAs)1-3

    • Symptoms >2 days a week 
    • SABA use for symptom control >2 days a week activities 
    • Interference with daily activities
  • At least 1 asthma exacerbation requiring use of OCSs over the past 12 months1,4
  • Compromised lung function (FEV1 <80% predicted)2,3
  • A history of elevated blood EOS count1*

EOS=eosinophils; FEV1=forced expiratory volume in one second; ICSs=inhaled corticosteroids; IL-5=interleukin-5; LABAs=long-acting beta agonists; OCSs=oral (systemic) corticosteroids; SABA=short-acting beta agonist.

*Blood EOS ≥400/mcL represents the patient population in CINQAIR clinical trials I, II, and III.1

Which patients may benefit from CINQAIR?

Find Out More

Teva Support Solutions®

REFERENCES: 1. CINQAIR Prescribing Information. West Chester, PA. Teva Respiratory, LLC. 2. National Asthma Education and Prevention Program (NAEPP). Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma–Full Report 2007. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute; August 2007. 3. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, 2016. www.ginasthma.org. Accessed December 14, 2020. 4. Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355-366.